Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies
Alzheimer's & Dementia · 2026-10 · 22 (10)
DOI: 10.1002/alz.71758 ↗Abstract
Abstract INTRODUCTION Anti‐amyloid antibody clinical trials with a high proportion of participants reaching treatment‐related amyloid clearance (TRAC) had positive clinical outcomes. We evaluated the aducanumab phase 3 program to determine whether TRAC during the double‐blind period was likewise associated with clinical benefit. METHODS We pooled ENGAGE and EMERGE (E/E) aducanumab‐treated participants in the amyloid positron emission tomography substudy who continued into the long‐term extension ≤ 134 weeks (continuously treated population) and/or returned to the EMBARK redosing study 0.7 to 2.5 years after termination of E/E (treatment gap population). Clinical outcomes were stratified by week 78 TRAC status. RESULTS TRAC participants had less clinical decline at week 78, week 134, and EMBARK baseline than non‐TRAC participants. Post‐TRAC, clinical decline was heterogeneous; approximately two thirds of TRAC participants had annualized decline of < 1 point on Clinical Dementia Rating Sum of Boxes. DISCUSSION In these exploratory analyses, week 78 TRAC status was associated with better clinical outcomes. CLINICAL TRIAL REGISTRATION NCT02484547, NCT02477800, NCT04241068
EUVIMED